# CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

6/14/24, 7:22	CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of W PM Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: http://www.jmir.org/2011/4/e126/ doi: 10.2196/jmir.1923 PMID: 22209829	Veb-based and Form	
_	<b>georges.khalil.uxr@gmail.com</b> Switch account	Oraft saved	-
	* Indicates required question		
	Your name * First Last Georges Khalil		
	Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada		
	University of Florida, Gainesville, USA		
	Your e-mail address * abc@gmail.com		
	gkhalil@ufl.edu		
	Title of your manuscript * Provide the (draft) title of your manuscript.		

Improved Risk Perception and Knowledge Following a Social Game-based Tobacco Prevention Program for Adolescents: A Pilot Randomized Comparative Trial

6/14/24	7:22 PM	
0/14/24	1.22 1 101	

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Name of your App/Software/Intervention \*

If there is a short and a long/alternate name, write the short name first and add the long

name in brackets.

Storm-Heroes

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Version 1

Language(s) \*

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

6/14/24, 7:22 PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Accessibility \* Can an enduser access the intervention presently? access is free and open access only for special usergroups, not open access is open to everyone, but requires payment/subscription/in-app purchases app/intervention no longer accessible Other:

Primary Medical Indication/Disease/Condition \*

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Tobacco use

Primary Outcomes measured in trial \* comma-separated list of primary outcomes reported in the trial

Vaping risk perception, Conventional tobacco r

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Your answer

6/14/24, 7:22 PN	CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Recommended "Dose" *
	What do the instructions for users say on how often the app should be used?
	O Approximately Daily
	O Approximately Weekly
	O Approximately Monthly
	O Approximately Yearly
	O "as needed"
	Other: Weekly for 5-7 weeks

Approx. Percentage of Users (starters) still using the app as recommended after \* 3 months

d

- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 0 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- O Other:

6/14/24, 7:22 PM OV	CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form erall, was the app/intervention effective? *
۲	yes: all primary outcomes were significantly better in intervention group vs control
0	partly: SOME primary outcomes were significantly better in intervention group vs control
0	no statistically significant difference between control and intervention
0	potentially harmful: control was significantly better than intervention in one or more outcomes
0	inconclusive: more research is needed
0	Other:
Art	icle Preparation Status/Stage *

At which stage in your article preparation are you currently (at the time you fill in this form)

not submitted yet - in early draft status

o not submitted yet - in late draft status, just before submission

submitted to a journal but not reviewed yet

submitted to a journal and after receiving initial reviewer comments

) submitted to a journal and accepted, but not published yet

- ) published
- Other:

6/14/24, 7:2	2 PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Journal *	
	If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")	
	O not submitted yet / unclear where I will submit this	
	O Journal of Medical Internet Research (JMIR)	
	O JMIR mHealth and UHealth	
	JMIR Serious Games	
	O JMIR Mental Health	
	JMIR Public Health	
	O JMIR Formative Research	
	O Other JMIR sister journal	
	O Other:	
	Is this a full powered effectiveness trial or a pilot/feasibility trial? *	
	Pilot/feasibility	
	O Fully powered	
	Manuscript tracking number *	
	If this is a JMIR submission, please provide the manuscript tracking number under "other"	

It this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

o ms number (yet) / not (yet) submitted to / published in JMIR

Other:

6/14/24, 7:22 PM TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? \*

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

yes

Other:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					(	Clear selection

	Does your paper address subitem 1a-i? * Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study							
	The title mentions "a Social Game-based" program.							
	1a-ii) Non-web-based components or important co-interventions in title							
	Mention non-web-based components or important co-interventions in title, if any (e.g.,							
	"with telephone support").							

## Does your paper address subitem 1a-ii?

subitem not at all important

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

 $\bigcirc$ 

 $\bigcirc$ 

essential

Clear selection

The title does not mention the presence of a non-web component.

 $\bigcirc$ 

6/14/24, 7:2	CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form 1a-iii) Primary condition or target group in the title							
	Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial							
		1	2	3	4	5		
	subitem not at all important	0	0	0	0	۲	essential	
							Clear selection	

Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The title mentions that the program is "for Adolescents"

1b) ABSTRACT: Structured summary of trial design, methods, results, and

conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

6/14/24, 7:22 PI	, 7:22 PM 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT								
	Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)								
		1	2	3	4	5			
	subitem not at all important	0	0	0	۲	0	essential		
							Clear selection		

Does your paper address subitem 1b-i?\*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The abstract mentions:	"the social	game Storn	n-Heroes"	and	"the non-so	cial prog	ram
ASPIRE"							

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					C	Clear selection

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The abstract mentions that "A study team member supervised both interventions"

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					C	Clear selection

## Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The abstract mentions that participants were "recruited in person"

6/14/24, 7:2	<sup>2 РМ</sup> 1b-iv) RESULTS section in abs	CONSORT- stract m	EHEALTH	(V 1.6.1) - S tain use	ubmission/F data	Publication F	Form			
	Report number of participants e intervention (e.g., attrition/adhe addition to primary/secondary o paper is reporting. If this inform adding it)	rence me outcomes	etrics, us s. (Note:	e over tir Only rep	ne, numl ort in the	per of log abstrac	gins etc.), in t what the main			
		1	2	3	4	5				
	subitem not at all important OOOOO essential									
							Clear selection			

## Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

It is mentioned "the social game Storm-Heroes (n=44) or the non-social program ASPIRE (n=35)"

# 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					(	Clear selection

6/14/24	7:22 PM	

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial was not negative

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection



CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The problem: "Adolescence forms a critical developmental phase that is particularly vulnerable to tobacco initiation"

The type of system/solution: "social game-based intervention, which is ideal for education systems (e.g., schools and after-school programs)".

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						Clear selection

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Adolescence forms a critical developmental phase that is particularly vulnerable to tobacco initiation"

"One particularly promising strategy for tobacco prevention is the application of games for health."

"Engaging gameplay has proven to be a promising avenue for tobacco prevention." "By including various gaming elements (eg, competition, collaboration, reward, goal setting, and storytelling), games can provide flexibility in addressing different issues pertaining to tobacco use."

"This line of research on gaming elements for tobacco prevention led to the design of a social game-based intervention, called Storm-Heroes, which is ideal for education systems (e.g., schools and after-school programs)."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The purpose of the current pilot study is to (1) compare the social game-based program Storm-Heroes to a non-social program with respect to adolescents' personal and social experience with the program, and (2) examine the role of adolescents' experience with the program in predicting higher perceived risk of vaping, perceived risk of conventional tobacco use, and knowledge by follow-up."

## METHODS

6/14/24, 7:22 PM

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form 3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"please refer to Appendix 1, which follows the Template for Intervention Description and Replication (TIDieR) checklist"

"ASPIRE is a computer-guided intervention, using entertaining videos and computer-based activities across five sessions over five weeks, each about 45 minutes long." Storm-Heroes "aims to educate adolescents about tobacco risks, environmental consequences, and impacts on social and mental well-being, incorporating 367 unique anti-tobacco messages based on the transtheoretical model (TTM) [28] and empowerment theory."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Unexpectedly, it was noticed that some participants would end up absent during a session. As a result, the grouping was reevaluated using the algorithm for the sessions when participants were absent."

6/14/24, 7:2	<sup>2 РМ</sup> 3b-i) Bug fixes, Downtimes, C	CONSORT-	EHEALTH ( Changes	(V 1.6.1) - S	ubmission/P	Publication F	Form		
	Bug fixes, Downtimes, Content ( description of changes to methor the intervention or comparator of functionality or content) (5-iii) a study design such as staff chan	ods there during the nd other	fore also e trial (e.g "unexpec	o include g., major cted ever	s importa bug fixes nts" that i	ant chan s or char may hav	ges made on nges in the		
		1	2	3	4	5			
	subitem not at all important OOOOOO essential								
							Clear selection		

## Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Unexpectedly, it was noticed that some participants would end up absent during a session. As a result, the grouping was reevaluated using the algorithm for the sessions when participants were absent."

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"For participation, adolescents needed to be 11 through 18 years of age and students in a middle school or high school."

6/14/24, 7:22	4a-i) Computer / Internet literacy									
	Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.									
		1	2	3	4	5				
	subitem not at all important	0	0	0	۲	0	essential			
						C	Clear selection			

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants also needed to be comfortable using a computer and the internet. "

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
					(	Clear selection




CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"After approval from the program directors, a verbal announcement reached adolescents at these sites, and interested adolescents completed child assent and parental permission."

## 4a-iii) Information giving during recruitment


Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



## Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"During recruitment, adolescents and their parents were informed that the study aimed to improve adolescent health through an interactive program in Florida after-school sites, that the study may take about two months and one week, and that they will engage in activities, surveys, and interviews. The incentive was described to potential participants, and they were informed that participation is voluntary and confidential, and the data would be securely stored at the University of Florida."



Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants completed surveys within a classroom setting and under supervision"

4b-i) Report if outcomes were (self-)assessed through online questionnaires Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
						Clear selection

Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We assessed the measures through Web-based closed surveys in a classroom setting, and a study staff was available for assistance."

4, 7:22 F	4b-ii) Report how institutional Report how institutional affiliat media], as affiliations with press use, and reactions with regards this may bias results)	al affiliati ions are c stigious he	lisplayed ospitals o	to poter or univers	ed ntial parti sities ma	cipants [ y affect v	volunteer rates,				
		1	2	3	4	5					
	subitem not at all important	0	0	۲	0	0	essential				
						(	Clear selection				
	Does your paper address su	bitem 4b	-ii?								
	Does your paper address subitem 4b-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study										
	"like this" to indicate direct que providing additional informatio	otes from n not in tl	your ma	. ,			•				
	"like this" to indicate direct que providing additional informatio	otes from n not in tl	your ma	. ,			•				
	"like this" to indicate direct quo providing additional informatio applicable/relevant for your stu	otes from n not in tl idy n group v	your ma ne ms, or vith suffi	briefly e	xplain wi	ny the ite	m is not				
	"like this" to indicate direct que providing additional informatio applicable/relevant for your stu Your answer 5) The interventions for each	otes from n not in th idy n group v y were ac ial, affilia liations o or develo	your ma ne ms, or vith suffi ctually a tions of f the dev oper of th	briefly e dcient de dministe the dev elopers, s ie softwa	xplain w etails to ered elopers, sponsors	allow rep sponso s, and ow beeds to b	m is not plication, rs, and owners ners [6] (if				
	<ul> <li>"like this" to indicate direct que providing additional informatio applicable/relevant for your stu.</li> <li>Your answer</li> <li>5) The interventions for each including how and when they</li> <li>5-i) Mention names, credential, affi authors/evaluators are owners</li> </ul>	otes from n not in th idy n group v y were ac ial, affilia liations o or develo	your ma ne ms, or vith suffi ctually a tions of f the dev oper of th	briefly e dcient de dministe the dev elopers, s ie softwa	xplain w etails to ered elopers, sponsors	allow rep sponso s, and ow beeds to b	m is not plication, rs, and owners ners [6] (if				
	<ul> <li>"like this" to indicate direct que providing additional informatio applicable/relevant for your stu.</li> <li>Your answer</li> <li>5) The interventions for each including how and when they</li> <li>5-i) Mention names, credential, affi authors/evaluators are owners</li> </ul>	n not in th n not in th idy n group v y were ac ial, affilia liations o or develo mentione	your ma ne ms, or vith suffi ctually a tions of f the dev oper of th ed elsewl	briefly e briefly e dcient de dministe the dev elopers, s here in th	etails to ered elopers, sponsors are, this n are manus	allow reponso sponso s, and ow beeds to b script).	m is not plication, rs, and owners ners [6] (if				

6/14/24, 7:22	PM Does your paper address sub Copy and paste relevant sectior "like this" to indicate direct quo providing additional informatior applicable/relevant for your stu	bitem 5-i ns from tl tes from n not in th	? ne manu: your mai	script (in nuscript)	clude qu , or elabo	orate on t	lotation marks his item by
	Your answer						
	5-ii) Describe the history/dev Describe the history/developme evaluations (e.g., focus groups, adoption/use rates and help wit	ent proce usability	ss of the testing),	applicat as these			
		1	2	3	4	5	
	subitem not at all important	0	0	0	0	0	essential
	Does your paper address sub Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stu	ns from tl tes from n not in th	ne manu: your mai	nuscript)	, or elabo	orate on t	his item by

Your answer

6/14/24, 7:22 F	™ 5-iii) Revisions and updating	CONSORT	-EHEALTH (	V 1.6.1) - S	ubmission/P	ublication Fo	orm			
Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic component such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).										
	1 2 3 4 5									
	subitem not at all important	0	0	0	0	0	essential			
	Does your paper address subitem 5-iii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Your answer									
	5-iv) Quality assurance meth Provide information on quality		e methor	ls to ensi	ure accu	racy and	quality of			
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.										
		1	2	3	4	5				
	subitem not at all important	0	0	0	0	0	essential			

6/14/24, 7:22 PM	<sup>и</sup> Does your paper address sub	CONSORT	-EHEALTH( V?	V 1.6.1) - S	ubmission/F	Publication Fo	orm					
	Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study											
	Your answer											
	5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used											
	Ensure replicability by publishing the source code, and/or providing screenshots/screen- capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.											
		1	2	3	4	5						
	subitem not at all important	0	۲	0	0	0	essential					
						C	Clear selection					

## Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

2 PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form 5-vi) Digital preservation									
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u> , and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.									
	1	2	3	4	5				
subitem not at all important	0	۲	0	0	0	essential			
Clear selection									
	5-vi) Digital preservation Digital preservation: Provide the change or disappear over the co archived (Internet Archive, <u>webc</u> screenshots/videos alongside th archived, consider creating dem	5-vi) Digital preservation Digital preservation: Provide the URL of the change or disappear over the course of the archived (Internet Archive, webcitation.or screenshots/videos alongside the article archived, consider creating demo pages	5-vi) Digital preservation Digital preservation: Provide the URL of the applic change or disappear over the course of the years; archived (Internet Archive, <u>webcitation.org</u> , and/o screenshots/videos alongside the article). As page archived, consider creating demo pages which are	5-vi) Digital preservation Digital preservation: Provide the URL of the application, but change or disappear over the course of the years; also mata archived (Internet Archive, <u>webcitation.org</u> , and/or publish screenshots/videos alongside the article). As pages behind archived, consider creating demo pages which are access 1 2 3	5-vi) Digital preservation Digital preservation: Provide the URL of the application, but as the change or disappear over the course of the years; also make sure t archived (Internet Archive, <u>webcitation.org</u> , and/or publishing the s screenshots/videos alongside the article). As pages behind login s archived, consider creating demo pages which are accessible with 1 2 3 4	5-vi) Digital preservation Digital preservation: Provide the URL of the application, but as the intervent change or disappear over the course of the years; also make sure the interv archived (Internet Archive, <u>webcitation.org</u> , and/or publishing the source co screenshots/videos alongside the article). As pages behind login screens c archived, consider creating demo pages which are accessible without login $1 \qquad 2 \qquad 3 \qquad 4 \qquad 5$ subitem not at all important			

## Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

## 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					(	Clear selection

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants accessed ASPIRE in the classroom within a group dedicated to receive the program. Participants accessed Storm-Heroes in the classroom through the board game on their tables and through the ASPIRE website.

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection


CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 6/14/24, 7:22 PM"ASPIRE is a computer-guided intermediating entertaining stide estated computer-based activities across five sessions over five weeks, each about 45 minutes long. It aims to enhance information retention and guide adolescents toward a tobacco-free lifestyle by engaging users through text, animations, videos, and activities. ASPIRE is evidence-based and tested for tobacco prevention. The intervention program is freely accessible online [26,27].

The Storm-Heroes intervention was developed collaboratively, involving a game designer, a research team with tobacco education expertise, and a youth design committee. Messages were designed using scientific evidence and message-framing strategies to impact tobacco risk perception, knowledge, and intention to use. The intervention aims to educate adolescents about tobacco risks, environmental consequences, and impacts on social and mental well-being, incorporating 367 unique anti-tobacco messages based on the transtheoretical model (TTM) [28] and empowerment theory. The design process resulted in a dynamic and socially engaging educational program, Storm-Heroes, combining digital and in-person elements. It seamlessly integrates online components with game-based tabletop activities, including ASPIRE-derived videos and game-based social activities for group interaction (Figure 1).

In Storm-Heroes, adolescents engage within a narrative. They play the role of friends on an island struck by a storm bringing tobacco products, harmful chemicals, and disease. To combat the storm's effects and save their island, teams embark on guests, participating in entertainment-education videos and activities. Before engaging in the program, adolescents are grouped using a validated social network algorithm. The grouping process ensures that each participant with high intentions to use tobacco is grouped with close friends who do not intend to use tobacco, facilitating constructive support during activities. Storm-Heroes offers adolescents five main activities, delivered on validated board game material. These include trivia with multiple-choice questions, acting where one member silently acts as others guess, drawing for guessing from sketches, speaking out for verbal clues, and teamwork scenarios presenting group dilemmas. The activities aim to engage teams in collaborative problem-solving around tobacco-related topics. Multimedia Appendix 1 describes the activities and how they are presented to players. The materials of Storm Heroes include informative background information in game-based social activities, such as scripts and task instructions, a tabletop game board, decks for board game cards, dice, tokens, and pons. The materials can be accessed by reaching out to the researchers.

Both ASPIRE and Storm-Heroes cover a comprehensive list of health topics related to tobacco, including its composition, effects on the body and brain, environmental impact, and strategies for tobacco prevention and advocacy (Multimedia Appendix 1). The content is structured consistently across both programs, covering aspects from understanding tobacco to building skills for a tobacco-free lifestyle and community activism."



#### Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Dosage and Frequency: 5 weekly sessions, 45 minutes each

## 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					(	Clear selection


CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A study team member was available for technical assistance and supervision." "A volunteer site staff trained in youth engagement was present to make sure that participants did not deviate from the requested data collection procedures."

## 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



## Does your paper address subitem 5-xi? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable for the current study.

#### 6/14/24, 7:22 PM

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					(	Clear selection

Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No co-interventions were provided beyond this program.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"At both baseline and 1.5-month follow-up, we measured perceived risk of vaping, perceived risk of using conventional tobacco products (cigarettes, cigars, and little cigars), and tobacco knowledge."

6/14/24, 7:2:	<sup>2 PM</sup> 6a-i) Online questionnaires: c CHERRIES items to describe If outcomes were obtained thro for online use and apply CHERR designed/deployed [9].	how the ugh onlir	questio	nnaires onnaires,	were de , describ	esigned/ e if they v	deployed vere validated			
		1	2	3	4	5				
	subitem not at all important	0	0	۲	0	0	essential			
						(	Clear selection			
	Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text While the surveys were online, they were administered in person, within a classroom setting.									
	6a-ii) Describe whether and h defined/measured/monitored		e" (incluc	ling inte	nsity of	use/dos	sage) was			
	Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.									
		1	2	3	4	5				
	subitem not at all important	0	۲	0	0	0	essential			

**Clear selection** 

Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text

Your answer

6/14/24, 7:22 PM 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained								
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).								
		1	2	3	4	5		
	subitem not at all important	0	۲	0	0	0	essential	
						C	Clear selection	

Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text

No qualitative feedback was obtained for this study.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes to trial outcomes.

7a) How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

6/14/24, 7:2	<sup>2 PM</sup> 7a-i) Describe whether and ho calculating the sample size Describe whether and how expe sample size.	·	cted atti	rition wa	is taken	into acc	count when
		1	2	3	4	5	
	subitem not at all important	0	0	0		0	essential
						C	Clear selection

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To conduct GLMMs using a target power of 0.85 and an effect size of 0.23 to perceived risk of vaping with an alpha value of .05, the estimated sample size was 45 participants [31]. We estimated that 75 adolescents would be needed to test the hypotheses, with an anticipated completion rate of approximately 60% (45/75). Considering the pilot nature of this study, this sample size was considered sufficient for the study of short-term secondary outcomes."

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no interim analyses or stopping guidelines for this study.

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The statistical team generated the random allocation of sites to each condition."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No restrictions to randomization. We randomized sites, under a cluster randomized trial.

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

sequentially numbered containers

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The statistical analyst generated the random allocation.

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

/24, 7:22 I	<sup>PM</sup> 11a-i) Specify who was blind Specify who was blinded, and blind the participants [1, 3] (thi blind outcome assessors, thos interventions (if any).	who wasn is should b	who was 't. Usuall ce clearly	sn't y, in web v acknow	-based tr ledged),	ials it is i but it ma	not possible to ay be possible to				
		1	2	3	4	5					
	subitem not at all important	0	0	0	0	۲	essential				
							Clear selection				
	Clear selection Does your paper address subitem 11a-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not										
	"like this" to indicate direct qu	otes from on not in th udy	your ma	nuscript)	, or elabo	orate on t	this item by				
	"like this" to indicate direct qu providing additional informatic applicable/relevant for your st	otes from on not in th udy cipants). r participa d which o (4a-ii) can w which in	your ma ne ms, or ants kne one was a create b	nuscript) briefly e w which the "con iases an	, or elabo xplain wh n interve nparator d certain	ntion wa	this item by m is not as the tions - discuss				
	"like this" to indicate direct qu providing additional informatic applicable/relevant for your st "a single-blinded format" (parti 11a-ii) Discuss e.g., whether "intervention of interest" and Informed consent procedures e.g., whether participants knew	otes from on not in th udy cipants). r participa d which o (4a-ii) can w which in	your ma ne ms, or ants kne one was a create b	nuscript) briefly e w which the "con iases an	, or elabo xplain wh n interve nparator d certain	ntion wa	this item by m is not as the tions - discuss				
	"like this" to indicate direct qu providing additional informatic applicable/relevant for your st "a single-blinded format" (parti 11a-ii) Discuss e.g., whether "intervention of interest" and Informed consent procedures e.g., whether participants knew	otes from on not in th udy cipants). r participa d which o (4a-ii) can v which in or".	your ma ne ms, or ants kne one was a create b terventio	nuscript) briefly e w which the "con iases an n was th	, or elabo xplain wh nparator d certain e "interve	ntion wa	this item by m is not as the tions - discuss				

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants did not know which intervention was of interest.

11b) If relevant, description of the similarity of interventions (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We made the comparison between Storm-Heroes and ASPIRE, a non-social program that is equivalent to Storm-Heroes in the order of sessions and type of health content. Table 2 describes the differences and similarities in design elements for Storm-Heroes and ASPIRE."

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed


PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We conducted statistical analyses using Stata version 14 (StataCorp LP). Considering cluster-randomization, we used multilevel generalized linear mixed-effect models (GLMMs). For all GLMMs, we identified demographic characteristics that may need to be included in the models. In every GLMM, an after-school site was modeled as a random effect nested within the intervention condition, and the intervention condition and time (and their interaction) were modeled as fixed effects."

### 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).



Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"with one-way analyses of variance (ANOVA) and chi-square tests, we examined attrition by testing differences between those retained and those lost to follow-up with respect to the outcome variables at baseline and other potential confounding factors."

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"controlling for confounders"


X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics co	mmittee	e approv	al			
	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					C	Clear selection

# Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The institutional review board for human subject research at the University of Florida approved this study."



Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

	1	2	3	4	5	
subitem not at all important	0	0	0	٢	0	essential
						Clear selection

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"the data would be securely stored at the University of Florida"

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In this study, over 100 adolescents expressed interest, and 79 enrolled, with the 4 sites randomly assigned to either Storm-Heroes or ASPIRE. Of these, 93.67% (74/79) completed the baseline survey. Among baseline participants, 55.40% (41/74) participated in the posttest experience survey, and 60.81% (45/74) participated in the 1.5-month follow-up survey"

13b) For each group, losses and exclusions after randomisation, together with reasons

6/14/24.	7:22 PM
0, 1 1, 2 1,	7.22

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram)

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No losses or exclusions were obtained or made after randomization.

# 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					(	Clear selection

# Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This can be found in Figure 2.

14a) Dates defining the periods of recruitment and follow-up

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study											
"The pilot study was conducted	in June o	of 2021" v	vith a 1.5	i-month f	ollow-up.						
14a-i) Indicate if critical "secu Indicate if critical "secular event Internet resources available or " resources"	ts" fell int	to the stu	Idy perio	d, e.g., si	gnificant	•					
Indicate if critical "secular event Internet resources available or "	ts" fell int	to the stu	Idy perio	d, e.g., si	gnificant	•					

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No critical secular event occured.

14b) Why the trial ended or was stopped (early)

PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address CONSORT subitem 14b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study was not ended or stopped early.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Table 3 presents the demographic characteristics by group."

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					(	Clear selection

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"There were no significant differential effects on tobacco knowledge as a function of age, ethnicity, race, and number of detentions. Having lower boardgame skills (P<0.001), being female (P=0.001), being non-Hispanic (P<0.001), having friends who vape (P<0.001), and having friends who smoke (P=0.010), and having parents with lower education level (P<0.001) moderated the effect of Storm-Heroes on tobacco knowledge."

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					(	Clear selection


CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In this study, over 100 adolescents expressed interest, and 79 enrolled, with the 4 sites randomly assigned to either Storm-Heroes or ASPIRE. Of these, 93.67% (74/79) completed the baseline survey. Among baseline participants, 55.40% (41/74) participated in the posttest experience survey, and 60.81% (45/74) participated in the 1.5-month follow-up survey (Figure 2)."

### 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).




### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The analysis was intent-to-treat.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)



# Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Intensity of use was not measured in this paper.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No binary outcomes were examined.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Pre-specified: "Controlling for group allocation, the results showed that the usability level of the program was related to a higher perceived risk of vaping (B=0.16, P=0.003) and conventional tobacco use (B=0.16, P=0.025) by follow-up. Attention to the program was also related to higher perceived risk of vaping (B=0.12, P=0.002) and conventional tobacco (B=0.14, P<0.001). Distraction was not related to either perceived risk of vaping (P=0.149) or perceived risk of conventional tobacco use (P=0.709). On the other hand, both, more attention (B=0.60, P<0.001) and less distraction (B=-0.37, P<0.001), were related to higher tobacco knowledge. A follow-up exploratory analysis of moderation indicated that distraction weakened the effect of receiving Storm-Heroes on tobacco knowledge by follow-up (Group-by-distraction: B=-6.67, P<0.001)."

6/14/24, 7:2	18-i) Subgroup analysis of comparing only users										
	A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).										
		1	2	3	4	5					
	subitem not at all important	0	0	0	۲	0	essential				
						(	Clear selection				

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harm or unintended effects occurred in this study.

Include privacy breaches, techn participants, but also incidents problems, and other unexpecter unintended positive effects [2].	such as p	perceived	d or real p	privacy b	reaches [	1], technical
	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
					(	Clear selection
Does your paper address sub	pitem 19	-i?				
		he manu	scrint (in	clude au	otes in a	iotation marks
Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stu	ns from tl otes from n not in th	your ma	nuscript)	, or elabo	orate on t	his item by
Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stu Your answer 19-ii) Include qualitative feed	ns from tl otes from n not in th dy	your ma ne ms, or	nuscript) briefly e	, or elabo xplain wł	brate on t	his item by n is not
Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stu Your answer	ns from tl otes from n not in th dy Iback fro om partici rtcoming s or uses.	your ma ne ms, or om partic ipants or s of the a This incl	nuscript) briefly e cipants o observa applicatio udes (if	, or elabo xplain wh or obser tions from on, espectavailable	vations m staff/re	his item by m is not from esearchers, if ey point to
Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stu Your answer 19-ii) Include qualitative feed staff/researchers Include qualitative feedback fro available, on strengths and sho unintended/unexpected effects	ns from tl otes from n not in th dy Iback fro om partici rtcoming s or uses.	your ma ne ms, or om partic ipants or s of the a This incl	nuscript) briefly e cipants o observa applicatio udes (if	, or elabo xplain wh or obser tions from on, espectavailable	vations m staff/re	his item by m is not from esearchers, if ey point to
Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stu Your answer 19-ii) Include qualitative feed staff/researchers Include qualitative feedback fro available, on strengths and sho unintended/unexpected effects	ns from the strom in not in the dy a strong the strong the strong term of the strong strong strong the strong strong strong the strong	your ma ne ms, or om partic ipants or s of the a This incl nded by	nuscript) briefly e cipants o observa applicatio udes (if a the devel	, or elabo xplain wh or obser tions from on, espec available opers.	vations m staff/re ially if th reasons	his item by m is not from esearchers, if ey point to

\_

I, 7:22 PN	M Does you	paper add	1633 300						
	"like this" to providing a	baste relevar to indicate d additional inf /relevant for	irect quot ormation	tes from not in th	your mai	nuscript)	, or elabo	orate on t	•
	Your answe	∍r							
	DISCUSSI	ON							
(									
	considerir NPT: In ad	retation con ng other rele dition, take in al expertise	evant evi nto accou	idence unt the cl	hoice of t	the comp	parator, la		ms, and partial blinding,
	considerin NPT: In ad and unequ 22-i) Rest starting w	ng other rele dition, take in al expertise ate study qu ith primary	evant evi nto accou of care pi uestions outcom	idence unt the cl roviders and sur es and p	hoice of t or center mmarize process	the comp is in each the ans outcom	barator, la n group swers su es (use)	ack of or uggested	partial blinding, d by the data,
	considerir NPT: In ad and unequ 22-i) Rest starting w Restate stu	ng other rele dition, take in al expertise ate study qu ith primary	evant evi nto accou of care pi uestions outcom	idence unt the cl roviders and sur es and p mmarize	hoice of t or center mmarize process the answ	the comp is in each the ans outcom	barator, la n group swers su es (use)	ack of or uggested	partial blinding,
	considerir NPT: In ad and unequ 22-i) Rest starting w Restate stu	ng other rela dition, take in al expertise ate study qu ith primary udy question	evant evi nto accou of care pi uestions outcom	idence unt the cl roviders and sur es and p mmarize	hoice of t or center mmarize process the answ	the comp is in each the ans outcom	barator, la n group swers su es (use)	ack of or uggested	partial blinding, d by the data,
	considerir NPT: In ad and unequ 22-i) Rest starting w Restate stu primary ou	ng other rela dition, take in al expertise ate study qu ith primary udy question	evant evi nto accou of care pr uestions outcom s and sur process	idence unt the cl roviders and sur es and p mmarize outcome	hoice of t or center mmarize process the answes (use).	the comp s in each e the ans outcom vers sug	barator, la n group swers su es (use) gested b	ack of or uggested ) y the dat	partial blinding, d by the data,

\_

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This paper describes a pilot cluster-randomized comparative trial examining the short-term effectiveness of Storm-Heroes, a social game-based intervention, in improving secondary tobacco-related outcomes, including perceived risk of tobacco use and tobacco knowledge. The paper also presents results from adolescents' experience with the intervention and its prediction of such outcomes. We hypothesized that adolescents' engagement with Storm-Heroes would result in (1) better quality of program experience, (2) improved perceived risk of vaping and conventional tobacco use, and (3) improved tobacco knowledge compared with the engagement in ASPIRE, a non-social, non-game-based equivalent program."

22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					C	Clear selection

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 22-ii?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"we must further examine strategies that may allow us to minimize distractions while maximizing engagement to boost the success of this intervention. Once the design of this program is clear, it becomes possible to further investigate its success by examining its long-term effects on actual tobacco use. Additionally, promoting peer-to-peer interactions can improve the impact of such interventions by facilitating knowledge dissemination and perceived tobacco risks. In the long run, going beyond these short-term outcomes, randomized trials with longitudinal data collection can provide valuable insights into the success of Storm-Heroes in preventing actual initiation of tobacco use and identify the factors that may promote long-term prevention outcomes. Second, future researchers can work to identify the specific program components and delivery methods that contribute to enhancing adolescents' experience and improving tobacco-related outcomes. Also, by identifying effective components responsible for an improved program experience, we can design novel interventions that can be tailored to target specific groups of adolescents and address their unique needs concerning different tobacco products."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

#### 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 20-i? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study ended with a relatively low retention rate (45/74, 60.8%). By the time this study reached 1.5-month follow-up, adolescents were at a transition out of the after-school summer period, entering the fall semester, and ultimately, several of them were not available to continue in the study. However, this did not stop 45 participants from reaching the 1.5-month follow-up assessment, and providing acceptable power for data analysis. In addition, our use of repeated-measures mixed effect modeling allowed us to account for missing data. Nevertheless, future work with adolescents may need to consider a larger sample size with a more suitable timing for data collection and a more controllable environment, such as school class sessions.

While this study showed a change in short-term outcomes (i.e., tobacco risk perception and knowledge), we did not examine a long-term change in tobacco use behavior. It must be noted, though, that this early pilot trial was meant to test the potential for adolescents' experience with Strom-Heroes to drive risk perception and knowledge. The current study did not inspect specific types of discussions engaged by adolescents as a result of their interaction. However, the results indicated relationships between exposure to Storm-Heroes and engagement in discussions related to the program and against tobacco.

From an implementation perspective, this study required the staff members to deliver the program to each classroom and moderate the sessions. This approach can limit wider reach and dissemination. Future efforts should adapt the procedures to allow teachers to deliver the program. Using Proctor's Framework for Implementation Outcomes, we can assess the program by evaluating teachers' adherence to key steps, engagement quality, satisfaction, and perceived feasibility."

21) Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial



6/14/24, 7:22	CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem 21-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	
	Your answer	
	OTHER INFORMATION	
	23) Registration number and name of trial registry	

Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Clinical Trials registry, NCT02703597

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The full trial protocol is not available for access.

6/14/24, 7:22 PM 25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R00DA044277 (Principal Investigator: Georges Khalil, MPH, PhD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					C	Clear selection

6/14/24, 7:22	PM CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Does your paper address subitem X27-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "There are no conflicts of interest for this study."	
	About the CONSORT EHEALTH checklist	
	As a result of using this checklist, did you make changes in your manuscript? * <ul> <li>yes, major changes</li> <li>yes, minor changes</li> <li>no</li> </ul>	
	What were the most important changes you made as a result of using this checklist? In the introduction and methods sections.	
	How much time did you spend on going through the checklist INCLUDING making * changes in your manuscript It took 60 minutes to go through the checklist and make changes.	

$\sim$	
$igodoldsymbol{()}$	yes
Ο	no
0	Other:
Wo	uld you like to become involved in the CONSORT EHEALTH group?
	s would involve for example becoming involved in participating in a workshop and ing an "Explanation and Elaboration" document
•	yes
0	no
0	Other:
	Clear selection
Any	other comments or questions on CONSORT EHEALTH
You	r answer
STO	DP - Save this form as PDF before you click submit
-	generate a record that you filled in this form, we recommend to generate a PDF of this e (on a Mac, simply select "print" and then select "print as PDF") before you submit it.
	en you submit your (revised) paper to JMIR, please upload the PDF as supplementary
file.	

\_

6/14/24, 7:22 PM Final step: Click submit !

Click submit so we have your answers in our database!

Submit

#### **Clear form**

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

# **Google** Forms

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc\_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en\_US&formkey=dGlKd2... 63/63